Requirement for Cyclin D1 Underlies Cell-Autonomous HIF2 Dependence in Kidney Cancer
We discovered that cyclin D1 is the key target of HIF2 driving the cell-autonomous proliferation of VHL-mutant kidney cancers and that cyclin D1 has targets beyond pRB in this setting. These findings have implications for treating kidney cancer with HIF2 inhibitors, alone or in combination with CDK4/6 inhibitors.
Authors
- Seth Goldman (ORCID: https://orcid.org/0000-0001-5096-3778)
- Paloma Cejas (ORCID: https://orcid.org/0000-0002-2090-7748)
- Shweta Kukreja (ORCID: https://orcid.org/0000-0001-6794-9016)
- Yenarae Lee
- Rong Li (ORCID: https://orcid.org/0009-0000-1046-9580)
- Xintao Qiu (ORCID: https://orcid.org/0000-0002-8560-7017)
- John G. Doench (ORCID: https://orcid.org/0000-0002-3707-9889)
- Sudeepa Syamala (ORCID: https://orcid.org/0000-0003-0476-3083)
- William R. Sellers (ORCID: https://orcid.org/0000-0002-3539-9803)
- Amy Goodale (ORCID: https://orcid.org/0000-0003-4294-5777)
- Devishi Kesar (ORCID: https://orcid.org/0000-0002-0949-2721)
- Nitin H. Shirole (ORCID: https://orcid.org/0000-0002-2579-456X)
- Henry W. Long (ORCID: https://orcid.org/0000-0001-6849-6629)
- Karen Louise Adelman (ORCID: https://orcid.org/0000-0001-5364-334X)
- William G. Kaelin (ORCID: https://orcid.org/0000-0002-0574-4856)
- Wenyu Yu
Institutions
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Howard Hughes Medical Institute (US)
- Harvard University (US)
- Harvard University Press (US)
- Dana-Farber Cancer Institute (US)
- Massachusetts Institute of Technology (US)
Publication Details
- Journal
- Cancer Discovery
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1158/2159-8290.cd-24-1378
- Citations
- 4
- Primary Topic
- Microtubule and mitosis dynamics
- Type
- article
- Field-Weighted Citation Impact
- 4.61
Funders
- Howard Hughes Medical Institute
- Dana-Farber Cancer Institute
- Dana-Farber/Harvard Cancer Center
- Hope Funds for Cancer Research
- National Institutes of Health